2023
DOI: 10.1016/j.ejphar.2023.175718
|View full text |Cite
|
Sign up to set email alerts
|

Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 65 publications
0
2
0
Order By: Relevance
“…Propranolol as a β1 and β2 adrenergic receptor blocker inhibits AOM DSS induced tumor development [42]. Similarly, cancers cells can have β adrenergic receptors and respond to the presence of catecholamines produced during stress.…”
Section: Discussionmentioning
confidence: 99%
“…Propranolol as a β1 and β2 adrenergic receptor blocker inhibits AOM DSS induced tumor development [42]. Similarly, cancers cells can have β adrenergic receptors and respond to the presence of catecholamines produced during stress.…”
Section: Discussionmentioning
confidence: 99%
“…Gene variants of PTGS1 inflammatory pathway were significantly associated with increased risk of CRC, and PTGS1 gene polymorphisms were identified as a risk factor for CRC. The beta2 adrenergic receptor ( ADRB2 ) is positively associated with T-cell exhaustion features in various tumors ( Lin et al, 2023 ). T cells are crucial anti-tumor lymphocytes, and the exhaustion of these cells is frequently linked to the malignant progression of malignancies.…”
Section: Discussionmentioning
confidence: 99%